All In Biotech

Drug Trial Radar · NCT00738062

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Jan 2008

Primary completion

Dec 2010

Study completion Dec 2010

Sponsor

Lead sponsor
Chelsea TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Conditions

  • Neurogenic Orthostatic Hypotension
  • Non-Diabetic Autonomic Neuropathy
  • Multiple System Atrophy
  • Dopamine Beta Hydroxylase Deficiency

Interventions

  • DroxidopaDrug

    100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

  • PlaceboDrug

    100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)Time frame: 14 days

Locations

54 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Dedicated Clinical Research

    Litchfield Park, Arizona

  • Xenoscience Inc.

    Phoenix, Arizona

  • Sun Health Research Institute

    Sun City, Arizona

  • The Parkinson's and Movement Disorders Institute

    Fountain Valley, California

  • Pacific Neuroscience Medical Group

    Oxnard, California

  • The Parkinson's Institute

    Sunnyvale, California

  • Electrophysiology Associates

    Colorado Springs, Colorado

  • Parkinson's Disease & Movment Disorder Center

    Boca Raton, Florida

  • Southeastern Integrated Medical

    Gainesville, Florida

  • Mayo Jacksonville Florida Department of Neurology

    Jacksonville, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Medical Associates of North Georgia

    Canton, Georgia

  • Saint Mary of Nazareth Hospital Center

    Chicago, Illinois

  • North Chicago VA Medical Center

    North Chicago, Illinois

  • Indiana Medical Research

    Elkhart, Indiana

  • JWM Neurology

    Indianapolis, Indiana

  • Kansas City Bone and Joint, PA

    Overland Park, Kansas

  • University of Louisville

    Louisville, Kentucky

  • University of Maryland Hospital

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Massachusetts Worcester

    Worcester, Massachusetts

  • Henry Ford Health System

    Southfield, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University Medical Center

    St Louis, Missouri

  • New Jersey Neuroscience Institute

    Edison, New Jersey

  • Kingston Neurological Associates, PC

    Kingston, New York

  • NYU Medical Center

    New York, New York

  • Columbia University Neurological institute of NY

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest University

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • COR Clinical Research, LLC

    Oklahoma City, Oklahoma

  • The Oregon Clinic

    Portland, Oregon

  • Vanderbilt University

    Nashville, Tennessee

  • Jacinto Medical Group, PA

    Baytown, Texas

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.